News

Dalcor Pharma licenses a late-stage investigational drug following a major discovery by the MHI

June 8, 2015

DALCOR PHARMA LICENSES A LATE-STAGE INVESTIGATIONAL CARDIOVASCULAR DRUG FOLLOWING MAJOR DISCOVERY BY MONTREAL HEART INSTITUTE (MHI) SCIENTISTS

New company DalCor to sponsor global phase III clinical trial to be led by MHI

Read more

MHI and AstraZeneca to screen samples for cardiovascular and diabetes genetic traits

May 13, 2015

The Montreal Heart Institute (MHI) today announced a collaboration with AstraZeneca, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes.

Read more